Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: ANIK stock price vs NSP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NSP's multiple
Needs NSP P/S.
Implied fair value · at ANIK's multiple
Needs ANIK P/S.
Metric by metric
Live quote
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ANIK FY 2025 (ended Dec 31, 2025) · NSP FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
Anika Therapeutics, Inc. · implied price per share
Bear
-$0.46
Base
-$0.55
Bull
-$0.63
Insperity, Inc. · implied price per share
Bear
-$56.11
Base
-$66.01
Bull
-$75.91
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.07x
8.02x
Net debt / EBITDA
Leverage against operating earnings
30.49x
-5.44x
Cash and equivalents
Liquid reserves on the balance sheet
$81.17M
$682.00M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$9.60M
$369.00M
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe ANIK can re-accelerate revenue growth and convert its 56.6% gross margin into improved operating leverage, then holding or buying can be justified because the current price is near the top of its historical band and NSP-implied P/S valuation is likely distorted by business-model differences.
ANIK trades at $20.16 versus a NSP-implied price of $2.42, which implies -88.0% downside on the stated P/S framework. However, NSP range is extremely wide ($0.04 to $219.33), and ANIK’s price also sits near the top of its own historical band ($18.14 to $22.18), suggesting the stock is not cheap on an absolute basis but may be bounded by its recent trading range.
Supporting Metrics
